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Abstract
Targeted temperature management (TTM) (primarily therapeutic hypothermia (TH)) after out-of-hospital cardiac
arrest (OHCA) has been considered effective, especially for adult-witnessed OHCA with a shockable initial rhythm,
based on pathophysiology and on several clinical studies (especially two randomized controlled trials (RCTs)
published in 2002). However, a recently published large RCT comparing TTM at 33 °C (TH) and TTM at 36 °C
(normothermia) showed no advantage of 33 °C over 36 °C. Thus, this RCT has complicated the decision to
perform TH after cardiac arrest. The results of this RCT are sometimes interpreted fever control alone is sufficient to
improve outcomes after cardiac arrest because fever control was not strictly performed in the control groups of the
previous two RCTs that showed an advantage for TH. Although this may be possible, another interpretation that the
optimal target temperature for TH is much lower than 33 °C may be also possible. Additionally, there are many points
other than target temperature that are unknown, such as the optimal timing to initiate TTM, the period between
OHCA and initiating TTM, the period between OHCA and achieving the target temperature, the duration of
maintaining the target temperature, the TTM technique, the rewarming method, and the management protocol after
rewarming. RCTs are currently underway to shed light on several of these underexplored issues. In the present review,
we examine how best to perform TTM after cardiac arrest based on the available evidence.
Keywords: Out-of-hospital cardiac arrest, Cardiopulmonary resuscitation, Post-cardiac arrest syndrome, Targeted
temperature management, Therapeutic hypothermia
Introduction
The 2010 International Consensus on Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care Science
with Treatment Recommendations (CoSTR) from the
International Liaison Committee on Resuscitation (ILCOR)
recommends therapeutic hypothermia (TH) (32–34 °C
for 12–24 h) for comatose adult patients upon return
of spontaneous circulation (ROSC) after out-of-hospital
cardiac arrest (OHCA) with a shockable initial rhythm.
It also states that TH may be considered for OHCA
with a non-shockable initial rhythm or in-hospital car-
diac arrest [1, 2]. This recommendation was based on
two landmark randomized controlled trials (RCT) pub-
lished in 2002 and supported by various subsequent
studies [3–6]. However, a recently published large RCT
raised questions about the effect of TH because that
RCT showed no advantage for TH compared with normo-
thermia (or fever control) [7].
In this review, we examine whether TH is beneficial
after cardiac arrest and how best to perform targeted
temperature management (TTM) after cardiac arrest on
the basis of current evidence.
Review
Rationale for TTM
There are three distinct phases of brain injury in cardiac
arrest [8, 9]. The first phase is intra-arrest ischemic injury
due to no flow. In this phase, energy failure, ischemic
depolarization of cell membranes, release of excitatory
amino acids, and cytosolic calcium overload occur. Irre-
versible injury can be caused by them when ischemia is
prolonged. The second phase is immediate reperfusion
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injury caused after ROSC. The resumption of oxidative
phosphorylation can lead to reactive oxygen species pro-
duction, mitochondrial calcium overload, and mitochon-
drial permeability transition, triggering cell death
signaling. The third phase is delayed post-reperfusion in-
jury. Secondary neuronal calcium overload, activation of
pathologic protease, and altered gene expression and in-
flammation can occur and can last for several days. All
three of these phases are potential targets for TTM.
Based on pathophysiological studies, hypothermia is
believed to elicit neurological protection in multiple
ways. Hypothermia decreases cerebral blood flow and
cerebral oxygen consumption approximately by 7–8 %
per 1 °C decline in temperature [10, 11]. Decreased cere-
bral metabolism protects the brain from further injury
after anoxic injury [12, 13]. In addition, hypothermia
affects two apoptotic cell death pathways. One is the in-
trinsic pathway under mitochondrial control, and the
other is the extrinsic pathway signaled by an extracellular
receptor [14]. Moreover, hypothermia reduces inflamma-
tion and free radical production [15]. Hypothermia can
also prevent brain edema caused by blood-brain barrier
disruption and increased vascular permeability following
ischemia-reperfusion injury [16, 17].
Based on clinical studies, hypothermia was considered
to improve outcomes after cardiac arrest. Two major
RCTs that provided evidence of a benefit of TH were
published in 2002 [3, 4].
In the European RCT, 275 adult comatose survivors
after witnessed OHCA of presumed cardiac origin with
shockable initial rhythm were enrolled [3]. Patients were
randomly assigned to receive TTM (or TH) (target
temperature, 32–34 °C; timing of initiation, at hospital
after ROSC; treatment duration, 24 h from the start of
cooling) or standard treatment with normothermia
(Table 1). TTM group had more favorable neurological
outcome (Glasgow-Pittsburgh cerebral performance cat-
egory (CPC) of 1 or 2) within 6 months after OHCA than
normothermia group (55 vs. 39 %; relative risk (RR), 1.40;
95 % confidence interval (CI), 1.08–1.81). In addition, 6-
month mortality was lower in the TTM group than in the
normothermia group (41 vs. 55 %; RR, 0.74; 95 % CI, 0.58–
0.95). In this study, the body temperature of the normo-
thermia group was not strictly managed. Therefore, the
average body temperature in the normothermia group
reached almost 38 °C because of the lack of fever control.
In the Australian RCT, 77 adult comatose survivors after
OHCA with shockable rhythm were enrolled [4]. Patients
enrolled on odd-numbered days of the month were
assigned to TTM (or TH) (target temperature, 33 °C; tim-
ing of initiation, in ambulance after ROSC; treatment dur-
ation, 12 h after hospital arrival), and patients enrolled on
even-numbered days of the month were assigned to
normothermia (Table 1). The TTM group had more
favorable neurological outcomes at discharge from hos-
pital than the normothermia group (49 vs. 26 %; P =
0.046). After adjustment for age and time from col-
lapse to ROSC, the odds ratio (OR) for a favorable neuro-
logical outcome with TTM compared to normothermia
was 5.25 (95 % CI, 1.47–18.76; P = 0.011). In this study,
the body temperature of the normothermia group was
relatively successfully maintained at 37.0 °C. How-
ever, the process of the randomization was inadequate
because of the assignment in accordance with the day
of the month, with patients assigned to hypothermia on
odd-numbered days.
Although these two RCTs were not flawless, they are
the basis for clinical practice guidelines that recommend
TH after cardiac arrest issued by various organizations
such as the American Heart Association (AHA), the Euro-
pean Resuscitation Council (ERC), and the Neurocritical
Care Society (NCS) (Table 1) [18–20]. A Cochrane sys-
tematic review also supported these recommendations [5].
However, a large RCT published in 2013 has raised ques-
tions about the benefit of TH [7]. In this large RCT, 939
unconscious adult survivors after OHCA of presumed car-
diac cause were enrolled irrespective of initial rhythm. Pa-
tients were randomly assigned to receive TTM of 33 °C (or
TH) (target temperature, 33 °C; timing of initiation, at
hospital after ROSC; treatment duration, 28 h from
randomization) or TTM of 36 °C (or normothermia with
strict fever control) (Table 1). At the end of the trial, the
mortality rates in both groups were similar (50 vs. 48 %;
hazard ratio (HR) with a temperature of 33 °C, 1.06; 95 %
CI 0.89–1.28; P = 0.51). At the 180-day follow-up, neuro-
logical outcomes were also similar in both groups, according
to a CPC of 3–5 (54 vs. 52 %; RR, 1.02; 95 % CI 0.88–1.16;
P = 0.78) or a modified Rankin scale of 4–6 (52 vs. 52 %;
RR, 1.01; 95 % CI 0.89–1.14; P= 0.87). The authors con-
cluded that TTM of 33 °C did not confer any benefit for un-
conscious survivors after OHCA relative to TTM of 36 °C.
TTM study makes it difficult to judge whether out-
comes after OHCA are improved by hypothermia. How-
ever, TTM study and previous two RCTs differed not
only in their implementation of strict fever control in the
control group but also in some other details (Table 1).
Therefore, the details of practical methods for TTM
should also be examined.
Practical methods for TTM
There are three phases in TTM (mainly TH): induction,
maintenance, and rewarming. Unsolved issues remain
in each phase, including the appropriate target
temperature, the timing of initiation, the duration from
cardiac arrest to initiation of TTM or the achievement
of target temperature, the treatment duration, the TTM
technique, and the rewarming method (Fig. 1).
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The optimal target temperature for neurologically favor-
able outcomes after OHCA is unclear at this time. Al-
though mild hypothermia (32–34 °C) has been strongly
recommended by various organizations on the basis of the
two RCTs published in 2002, several subsequent studies,
and pathophysiological findings, the recently published
RCT comparing TTM of 33 °C with TTM of 36 °C showed
no beneficial effect of mild hypothermia compared with
normothermia (with strict fever control) [1–7, 10–19]. This
could mean that strict fever control alone may be sufficient
to improve neurological outcomes among OHCA com-
pared with mild hypothermia, or that the optimal target
temperature may be lower than 33 °C. However, the
differences in the main results of the three RCTs that
compared TH with normothermia may be caused by dif-
ferences in their implementations of TTM other than the
target temperature (Table 1). To determine the optimal
target temperature for improving neurological outcomes
after OHCA, further study will be required; comparing a
range of target temperature levels without varying other
aspects of TTM. An RCT comparing TTM at 31 °C and
TTM at 34 °C (CAPITAL CHILL (NCT02011568)) is cur-
rently recruiting, and it may provide further clarification.
Timing of initiation and duration from cardiac arrest to
initiation or target temperature
The optimal timing for initiating TTM is unknown. In
addition, the effect on outcomes of delay between the
onset of cardiac arrest and initiating TTM or achieving
the target temperature is not well understood.
Animal experiments have shown that earlier initiation
of TH increases the efficacy of TH [21, 22] and that sur-
vival rates are high and brain injury is mild when TH is
initiated during the intra-arrest period before ROSC [23,
24]. However, similar results have not always been ob-
tained in studies involving human subjects. A registry
study in Scandinavia including 986 TH-treated OHCA
patients, the largest-scale study of this issue, did not re-
veal any relationship between neurologic outcomes
and the length of time from cardiac arrest until the initi-
ation of TH (median 90 min, p = 0.48) or until the target
temperature was achieved (median 260 min, p = 0.91) [6].
However, according to a study in the USA using data from
the International Cardiac Arrest Registry (INTCAR),
which included 172 OHCA patients treated with TH,
every 5-min delay in initiating TH (mean 94.4 min) was
associated with a worsening in neurologic outcomes at in-
tensive care unit (ICU) discharge (OR 1.06, 95 % CI 1.02–
1.10), at hospital discharge (OR 1.06, 95 % CI 1.02–1.11),
and 1 month after hospital discharge (OR 1.08, 95 % CI
1.03–1.13) [25]. Furthermore, neurologic outcomes
1 month after discharge worsened with every 30-min
delay in achieving the target temperature (OR 1.17, 95 %
CI 1.01–1.36). In another study in the USA, which in-
cluded 140 OHCA patients who had achieved ROSC, a
20 % increase in the risk of death (95 % CI 4–39 %) was
observed for every hour of delay in initiation of TH [26].
In a study in Germany that included 49 successfully re-
suscitated OHCA and in-hospital cardiac arrest (IHCA)
patients, neurologic outcomes worsened for every hour
delay in reaching the target temperature (OR 0.69, 95 %
CI 0.51–0.98) [27]. It is necessary to note that
Fig. 1 Time course of targeted temperature management
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comparatively long delays, approximately 80–150 min
from cardiac arrest to initiation of TH and approximately
260–410 min from cardiac arrest to achievement of target
temperature, were observed in these studies.
Several studies have examined the feasibility, safety, and
efficacy of pre-hospital TH with the purpose of more
quickly initiating TH and achieving the target temperature.
The safe and effective introduction of TH appears to be
feasible not only after ROSC [28–31] but also before ROSC
(intra-arrest or during resuscitation) [32, 33].
There have been many RCTs investigating the relation-
ship between pre-hospital TH after ROSC and outcomes
after OHCA [34–36], and meta-analyses have also been
conducted [37, 38]. In all studies, pre-hospital TH de-
creased core temperature on hospital arrival and reduced
the time to target temperature, but improvements in sur-
vival rates and neurologic outcomes were not shown.
Animal experiments and clinical studies have shown
decreases in myocardial infarction size and increases in
ROSC rates when TH was initiated before ROSC (intra-
arrest) [39, 40], and a systematic review showed that, al-
though clinical data are limited, intra-arrest TH improved
not only ROSC rates but also survival rates and favor-
able neurologic outcomes [41]. Two large RCTs examin-
ing pre-hospital intra-arrest TH by intranasal cooling
(PRINCESS (NCT01400373)) or by rapid infusion of cold
normal saline (RINSE (NCT01173393)) are ongoing.
Although there is currently little evidence supporting
earlier initiation of pre-hospital TH after ROSC, its
introduction before ROSC may be effective; thus, the
results of the RCTs currently in progress will provide
important clarification.
Treatment duration
The 2010 AHA guidelines states that the optimal duration
of TH is at least 12 h and may be more than 24 h [18].
This recommendation is based on two RCTs that showed
beneficial effects of TH for adult OHCA with a shockable
initial rhythm [3, 4]. Although TH for up to 72 h has been
used safely in newborns, the effect of longer TH duration
on outcomes for adult OHCA has not been studied [42,
43]. An RCT of prolonged TH (at 32–34 °C for 24 vs.
48 h) (TTH48 (NCT01689077)) is now recruiting, and it
may provide further information.
TTM techniques
Common methods used for cooling include rapid
infusion of ice-cold IV fluid, ice packs, water-circulating
blankets, air-circulating blankets, water-circulating gel-
coated pads, and intravascular cooling devices (Table 2).
Moreover, there are methods that use cardiopulmonary
bypass [44], nasopharyngeal cooling [45], transnasal evap-
orative cooling [33, 46], cold-air tents [3], and cooling hel-
mets [47, 48], among others. The CoSTR from ILCOR
Table 2 Cooling techniques
Rapid infusion of ice-cold IV










Pre-hospital ◯ × × × ×
After hospital arrival ◯ △ △ △ ×
Specialized devices Specialized devices Specialized devices Specialized devices
intravascular catheterization
Non-invasiveness ◯ ◯ ◯ ◯ ×
intravascular catheterization
Cooling rate × ◯ × ◯ ◯
0.32 ± 0.24 °C/h 1.33 ± 0.63 °C/h 0.18 ± 0.20 °C/h 1.04 ± 0.14 °C/h 1.46 ± 0.42 °C/h
Maintenance phase
Stabilitya × × × × ◯
69.8 ± 37.6 % 50.5 ± 35.9 % 74.1 ± 40.5 % 44.2 ± 33.7 % 3.2 ± 4.8 %
Convenience × △ △ ◯ ◯
Frequent manual exchange Manual control Manual control Automated control Automated control
Inexpensiveness ◯ △ △ × ×
Specialized devices Specialized devices Specialized devices Specialized devices
aThe percentage of time the patient’s temperature was out of range more than 0.2 °C below or above the target temperature
Reference: [49] Hoedemaekers CW, Ezzahti M, Gerritsen A, van der Hoeven JG. Comparison of cooling methods to induce and maintain normo- and hypothermia
in intensive care unit patients: a prospective intervention study. Crit Care 2007; 11: R91
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lists rapid infusion of ice-cold IV fluid and ice packs as
feasible, safe, and simple introduction methods that do
not require any specialized devices [1, 2].
In an RCT, the following five cooling methods were
compared in 50 ICU patients who required strict TTM,
including 16 OHCA patients and 4 IHCA patients:
(1) rapid infusion of 30 ml/kg cold fluids and ice-cold
packs (conventional cooling), (2) water-circulating blan-
kets, (3) air-circulating blankets, (4) water-circulating gel-
coated pads, and (5) intravascular cooling devices [49]
(Table 2). Temperature decline was greater with the
water-circulating blankets (1.33 °C/h), water-circulating
gel-coated pads (1.04 °C/h), and intravascular cooling
devices (1.46 °C/h) compared to conventional cooling
(0.32 °C/h) and the air-circulating blankets (0.18 °C/h)
(p < 0.05). Moreover, the percentage of time for which
the patient’s temperature was more than 0.2 °C below
or above the target temperature was significantly lower
with the intravascular cooling device (3.2 %) than with
other methods (water-circulating gel-coated pad, 44.2 %;
water-circulating blanket, 50.5 %; conventional cooling,
69.8 %; air-circulating blanket, 74.1 %; p < 0.05). Based on
these findings, an intravascular cooling device may be an
efficient way to achieve the target temperature earlier and
to maintain a stable temperature.
Two RCTs have been conducted to evaluate the clin-
ical impact of intravascular cooling on outcomes after
OHCA. One RCT compared invasive advanced internal
cooling (CoolGard®) with non-invasive advanced external
cooling (ArcticSun®) [50], and the other RCT compared
invasive advanced internal cooling (CoolGard®) with
non-invasive basic external cooling (using fans, cooling
tents if possible, and ice packs) [51]. These two RCTs
showed no beneficial effects of intravascular cooling on
survival or favorable neurological outcomes after OHCA.
However, the target temperature was more strictly main-
tained with intravascular cooling. The time to achieve the
target temperature with advanced internal cooling (Cool-
Gard®) was similar to that with advanced external cooling
(ArcticSun®) but significantly shorter than that with basic
external cooling. Bleeding complications were more fre-
quent with intravascular cooling.
Thus, it appears that intravascular cooling devices are
beneficial for reducing time to target temperature and im-
proving strict maintenance of the target temperature, but
this does not always lead to improved outcomes.
Currently, there is insufficient evidence to recommend
any specific cooling method. Therefore, it is necessary to
fully understand the advantages and disadvantages of each
cooling method and consider which combination
of methods is appropriate for each facility.
When TH is initiated, cooling methods that do not re-
quire specialized devices, such as rapid infusion of ice-
cold IV fluid and ice packs, as described in the ILCOR
guidelines [1, 2], may be useful because they can be im-
plemented anytime and anywhere (including pre-hospital,
during transport, or during resuscitation) and are safe and
inexpensive. Conversely, during the maintenance phase,
the selection of a cooling method that matches the avail-
able budget, manpower, and equipment of each facility
may be desirable.
Rewarming
According to the ERC guidelines, because plasma elec-
trolyte concentrations and effective intravascular volumes
and metabolic rates are likely to change suddenly, it is rec-
ommended to perform rewarming slowly [19]. The rec-
ommended rate for rewarming in the ERC Hypothermia
After Cardiac Arrest Registry (ERC HACA-R) is 0.25–
0.5 °C/h [52].
In a retrospective cohort study including 128 patients
treated with TH after cardiac arrest, the authors exam-
ined rewarming method (active vs. passive), rewarming
speed (≧0.5 °C/h vs. <0.5 °C/h), and the relationship be-
tween fever (>38 °C) and poor outcomes. The odds ratios
for poor outcomes after adjustment for confounders were
as follows: active rewarming, 1.51 (95 % CI 0.64–3.58, p =
0.35); rewarming speed ≧0.5 °C/h, 2.61 (95 % CI 0.88–
7.73, p = 0.08); fever, 0.64 (95 % CI 0.31–1.30, p = 0.22)
[53]. There were no significant associations between
rewarming method and outcomes in this study. It is ex-
pected that RCTs will also be performed to investigate op-
timal rewarming methods.
The AHA guidelines recommend treatment of hyper-
thermia following rewarming of the patient through TH
[18]. This is based on several studies that have shown a
relationship between hyperthermia in post-cardiac arrest
syndrome (PCAS) and poor outcomes [54–57]. Based
on these studies, hyperthermia should be avoided for
48–72 h after ROSC.
In the Penn Alliance for Therapeutic Hypothermia
(PATH) Registry, a multicenter US clinical registry that
includes 167 patients who survived 24 h after post-TTM
rewarming, the relationships between rebound pyrexia
(defined as temperature >38 °C) and clinical outcomes
were examined [58]. After post-TTM rewarming, pyrexia
was observed in 41 % of patients, and the median
temperature was 38.7 °C. There were no significant differ-
ences between the pyrexia group and the no pyrexia
group in survival rate (54 vs. 52 %, p = 0.88) or favorable
neurologic outcome (70 vs. 82 %, p = 0.21). However,
when the authors compared marked pyrexia (greater than
the median pyrexia of 38.7 °C) with no or milder pyrexia
(below the median), the survival rate did not differ (40 vs.
56 %, p = 0.16), but marked pyrexia was associated
with more frequent poor neurological outcomes (58
vs. 80 %, p = 0.04). Based on these findings, it may be
that there is a relationship between higher pyrexia
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after post-TTM rewarming and more severe brain in-
jury or that there is a threshold temperature above
which an effect on outcomes is detectable. However, be-
cause their study design can only indicate an association,
not a causal relationship, it is difficult to resolve these is-
sues decisively. Further study is necessary to identify the
maximum safe temperature after post-TTM rewarming,
and the duration for which temperature management
should be continued, and the importance of avoiding
hyperthermia after completion of rewarming.
Which patients benefit the most from TTM
In this review, we mainly examined how best to perform
TTM after OHCA. However, we also know very little
about which patients benefit the most from TTM. What
we do know is that TTM seems to have the most impact
on favorable outcomes among patients with an initial
shockable rhythm [3, 4, 59]. Several studies have exam-
ined whether the effectiveness of TTM might depend
on the time, such as no-flow time, low-flow time, or
total down-time [59–62], or on the severity of anoxic-
ischemic injury [63–65]. Well-designed studies will be re-
quired to identify who can benefit the most from TTM.
Conclusions
It is not yet possible to identify the most appropriate
practical method for TTM after OHCA. A recently pub-
lished large RCT showed no advantage for TTM of 33 °
C in comparison with TTM of 36 °C, but it would be
premature to discard the numerous previous studies and
the pathophysiology that support the efficacy of TH. On
the other hand, this large RCT also confirmed that strict
TTM is essential. Although it remains undetermined
whether TH should be performed, it is necessary to
surely manage temperature to avoid hyperthermia. RCTs
concerning the optimal target temperature, optimal timing
of initiation, and optimal duration of treatment are cur-
rently in progress. To determine whether TH is beneficial
after cardiac arrest and how best to perform TTM after
cardiac arrest, the ongoing RCTs deserve careful
attention.
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